Cronos Group Inc CRON

Investing.com -- Cronos Group’s manufacturing capacity, cannabis genetics and branded product portfolio are drawing renewed attention after the company showcased its operations at an investor day, prompting an analyst to raise its 12-month price target to C$5.50 from C$5.25.

Global markets are adjusting to higher long term interest rates, with bond yields in countries like Australia moving toward levels not seen in years. That shift keeps investors focused on balance sheets and cash flow rather than hype. For Canadian penny stocks, it creates a window to look at lower priced businesses that still keep their finances in order. This article breaks down three such opportunities from our financially focused screener. The three penny stocks covered below are only a...

Cronos Group (NASDAQ:CRON) used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation. Chief Executive Officer Mike Goren

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location. Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentations The session will be webcast today starting at 12:00 p.m. ET. Webcast registr

Higher energy costs and supply chain risks are putting pressure on global manufacturers, which makes financial resilience matter more than ever for smaller companies. For Canadian penny stocks, that creates a window where stronger balance sheets and cleaner cash profiles can stand out. This article walks through three financially solid, low-priced stocks from our screener that aim to combine speculative upside with tighter risk controls. The three tickers in this piece are only a small...

Trulieve and Cronos are turning stronger results into market-beating gains.

Registration is now open for Cronos’ first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, will host its first Investor Day on Thursday, September 24, 2026, at its Growing Company (“Cronos GrowCo”) Kingsville location. “We’re excited to host our first Cronos Investor Day from our Kingsville, Ontario, Cronos GrowCo locat

On August 6, Cronos Group (NASDAQ:CRON) reported second quarter results that finally paired growth with profitability. Net revenue climbed 58% year over year to $53.0 million, but the number that stands out is the bottom line: net income of $35.7 million, compared with a $38.5 million loss a year earlier. The company also disclosed a […]

Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch. The new SOURZ by Spinach® Blue Raspberry Lemonade Fully Blaste

Global bond markets are now pricing in higher policy rates as inflation stays in focus. That backdrop pushes investors toward parts of the market where every dollar is scrutinised, including penny stocks. Financially Fit Penny Stocks apply a strict lens to smaller companies under 5 a share, with an emphasis on balance sheet strength. This article highlights 3 stocks from the screener that aim to balance potential with resilience. The three stocks below are just a starting sample from this...

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Despite regulatory hurdles, Cronos Group Inc (CRON) posts record net revenue and gross profit, driven by strong Canadian brand performance and international momentum.

Cronos Group Inc. has reported its second-quarter 2026 results, with sales rising to US$70.6 million and revenue to US$53.01 million, alongside a shift from a net loss to net income of US$32.09 million compared with the same period last year. This move into profitability, with basic earnings per share from continuing operations at US$0.09 versus a loss per share a year earlier, highlights a clear improvement in operating performance over both the quarter and first half of 2026. We’ll now...

Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis Delivered record net revenue in Canada, with Spinach® maintaining #1 market share in vapes and edibles1 Tenth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the #1 cannabis brand2 Generated record net revenue outside Canada and Israel, led by strong demand for